GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirnaomics Ltd (HKSE:02257) » Definitions » LT-Debt-to-Total-Asset

Sirnaomics (HKSE:02257) LT-Debt-to-Total-Asset : 0.25 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sirnaomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sirnaomics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.25.

Sirnaomics's long-term debt to total assets ratio increased from Dec. 2023 (0.10) to Dec. 2024 (0.25). It may suggest that Sirnaomics is progressively becoming more dependent on debt to grow their business.

Sirnaomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sirnaomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirnaomics LT-Debt-to-Total-Asset Chart

Sirnaomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.02 0.02 0.06 0.10 0.25

Sirnaomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.06 0.10 0.23 0.25

Sirnaomics LT-Debt-to-Total-Asset Calculation

Sirnaomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=55.246/220.213
=0.25

Sirnaomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=55.246/220.213
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirnaomics  (HKSE:02257) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sirnaomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sirnaomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirnaomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirnaomics Ltd (HKSE:02257) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
HKSE:02197 HKSE:00690 HKSE:09939 HKSE:08158 HKSE:01228 HKSE:02185 HKSE:02898 HKSE:06628 HKSE:02126 HKSE:02511 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No.218 Xinghu Street, Unit 415, A4 Building, Suzhou Industrial Park, Suzhou, CHN
Website
https://www.sirnaomics.com
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China.
Executives
Poon Hung Fai 2101 Beneficial owner
Lu Yang 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Dai Xiaochang 2201 Interest of corporation controlled by you
Yan Xia Ling 2202 Interest of your spouse
Ceng Yu 2201 Interest of corporation controlled by you
Li Jie 2201 Interest of corporation controlled by you
Li Lele 2202 Interest of your spouse
Shanghai Chongshi Enterprise Management Partnership(lp) 2101 Beneficial owner
Shenzhen Qianhai Rotating Boulder Fund Management Co.,ltd 2201 Interest of corporation controlled by you
Shenzhen Rotating Boulder Tiancheng The Second Investment Partnership (limited Partnership) 2201 Interest of corporation controlled by you
Shenzhen Rotating Boulder Tiancheng The Third Investment Partnership (limited Partnership) 2201 Interest of corporation controlled by you

Sirnaomics Headlines

No Headlines